N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure

European Journal of Epidemiology

Volumn 24, Issue 7, 2009, Pages 363-368

  Mayer Jr , Otto ^a   Šimon, Jaroslav ^a   Plášková, Markéta ^b   Cífková, Renata ^b   Trefil, Ladislav ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Coronary artery disease; EUROASPIRE II; Mortality; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HORMONE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; RISK ASSESSMENT;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CZECH REPUBLIC; FEMALE; HEALTH SURVEYS; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 67449123068     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-009-9339-6     Document Type: Article

References (19)

1. ER Levin DG Gardner WK Samson 1998 Natriuretic peptides N Engl J Med 339 321 328 10.1056/NEJM199807303390507
2. C Hall 2004 Essential biochemistry and physiology of (NT-pro)BNP Eur J Heart Fail 6 257 260 10.1016/j.ejheart.2003.12.015
3. JP Goetze C Christoffersen M Perko H Arendrup JF Rehfeld J Kastrup LB Nielsen 2003 Increased cardiac BNP expression associated with myocardial ischemia FASEB J 17 1105 1107
4. RS Gardner F Ozalp AJ Murday SD Robb TA McDonagh 2003 N-terminal pro-brain natriuretic peptide A new gold standard in predicting mortality in patients with advanced heart failure Eur Heart J 24 1735 1743 10.1016/j.ehj.2003.07.005
5. F Hartmann M Packer AJ Coats MB Fowler H Krum P Mohacsi JL Rouleau M Tendera A Castaigne SD Anker I Amann-Zalan S Hoersch HA Katus 2004 Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial Circulation 110 1780 1786 10.1161/01.CIR.0000143059.68996.A7
6. SK James B Lindahl A Siegbahn M Stridsberg P Venge P Armstrong ES Barnathan R Califf EJ Topol ML Simoons L Wallentin 2003 N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy Circulation 108 275 281 10.1161/01.CIR.0000079170. 10579.DC
7. JA de Lemos DA Morrow JH Bentley T Omland MS Sabatine CH McCabe C Hall CP Cannon E Braunwald 2001 The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes N Engl J Med 345 1014 1021 10.1056/NEJMoa011053
8. AM Richards R Doughty MG Nicholls S MacMahon N Sharpe J Murphy EA Espiner C Frampton TG Yandle 2001 Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group J Am Coll Cardiol 37 1781 1787 10.1016/S0735-1097(01)01269-4
9. C Kragelund B Gronning L Kober P Hildebrandt R Steffensen 2005 N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease N Engl J Med 352 666 675 10.1056/NEJMoa042330
10. TJ Wang MG Larson D Levy EJ Benjamin EP Leip T Omland PA Wolf RS Vasan 2004 Plasma natriuretic peptide levels and the risk of cardiovascular events and death N Engl J Med 350 655 663 10.1056/NEJMoa031994
11. EUROASPIRE II Group 2001 Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Eur Heart J 22 554 572 10.1053/euhj.2001.2610
12. T Mueller A Gegenhuber W Poelz M Haltmayer 2003 Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease Clin Chem 49 976 979 10.1373/49.6.976
13. T Omland A Persson L Ng R O'Brien T Karlsson J Herlitz M Hartford K Caidahl 2002 N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes Circulation 106 2913 2918 10.1161/01.CIR.0000041661. 63285.AE
14. BA Groenning I Raymond PR Hildebrandt JC Nilsson M Baumann F Pedersen 2004 Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population Heart 90 297 303 10.1136/hrt.2003.026021 (Pubitemid 38250725)
15. S Yusuf S Hawken S Ounpuu T Dans A Avezum F Lanas M McQueen A Budaj P Pais J Varigos 2004 INTERHEART Study Investigators: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 937 952 10.1016/S0140-6736(04)17018-9
16. S Blankenberg MJ McQueen M Smieja J Pogue C Balion E Lonn HJ Rupprecht C Bickel L Tiret F Cambien H Gerstein T Münzel S Yusuf 2006 HOPE Study Investigators. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation 114 201 208 10.1161/ CIRCULATIONAHA.105.590927
17. D De Bacquer G De Backer E Ostor J Simon K Pyorala 2003 EUROASPIRE I Study Group.Predictive value of classical risk factors and their control in coronary patients: a follow-up of the EUROASPIRE I cohort Eur J Cardiovasc Prev Rehabil 10 289 295 10.1097/00149831-200308000-00012
18. DL Bhatt PG Steg EM Ohman AT Hirsch Y Ikeda JL Mas S Goto CS Liau AJ Richard J Rother PW Wilson 2006 REACH Registry Investigators International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis JAMA 295 180 189 10.1001/jama.295.2.180
19. WL Miller HN Skouri 2009 Chronic systolic heart failure, guideline-directed medical therapy, and systemic hypotension-less pressure but maybe more risk (does this clinical scenario need more discussion?) J Card Fail 15 101 107 10.1016/j.cardfail.2008.07.228